左西孟旦联合脑心通胶囊治疗急性心力衰竭的疗效及对血清NT-proBNP，Galectin-3，ET-1及CystatinC水平的影响

目的:分析左西孟旦联合脑心通胶囊治疗急性心力衰竭的临床疗效及对血清氨基末端B型钠尿肽前体(NT-proBNP)、半乳糖凝集素(Galectin-3)、内皮素-1(ET-1)、半胱氨酸蛋白酶抑制剂C(CystatinC)水平的影响。方法:选取2015年3月至2016年6月我院收治的90例急性心力衰竭患者,按抽签法将患者随机分为观察组(n=45)和对照组(n=45),对照组患者给予单纯左西孟旦治疗,观察者患者在此基础上联合应用脑心通胶囊治疗。比较两组患者的临床疗效、心功能指标、血压、心率、不良反应的发生情况及治疗前后血清NT-proBNP、Galectin-3、ET-1和CystatinC水平的变化。结果:治疗后,观察组总有效率为93.33%,比对照组显著升高(77.78%)(P0.05)。两组治疗后患者的左室部分缩短(LVFS)、左心射血分数(LVEF)、每搏输出量(SV)水平均较治疗前增高,血压、心率及血清NT-proBNP、Galectin-3、ET-1、CystatinC水平均较治疗前明显下降,且观察组患者的LVFS、LVEF、SV水平明显高于对照组(P0.05),血压、心率及血清NT-proBNP、Galectin-3、ET-1、CystatinC水平明显低于对照组(P0.05)。结论:左西孟旦联合脑心通胶囊治疗能提高急性心力衰竭的治疗效果,显著降低血清NT-proBNP、Galectin-3、ET-1和CystatinC水平,安全性较高。

Clinical Efficacy of Levosimendan Combined with Naoxintong Capsule in Treatment of Acute Heart Failure and Effects on Serum NT-proBNP, Galectin-3, ET-1 and Cystatin C Levels

ABSTRACT Objective: To study the clinical efficacy of levosimendan combined with naoxintong capsule in the treatment of acute heart failure and effects on the serum amino terminal B type natriuretic peptide precursor(NT-proBNP), Galectin-3, endothelin 1 (ET-1), Cystatin C levels. Methods: 90 patients with acute heart failure from March 2015 to June 2016 in our hospital were selected and divided into observation group (n=45) and control group (n=45) by lottery method. Patients in the control group were treated by levosimendan alone. Patients in the observation group were treated by Naoxintong capsule combined with levosimendan. The clinical effect, changes of serum NT-proBNP, galectin-3, ET-1, cystatin C levels before and after treatment and the incidence of adverse reactions were compared between two groups. Results: After treatment, the total effective rate was 93.33% in the observation group, which was higher than that in the control group (77.78%) (P<0.05); the left ventricular fractional shortening, left ventricular ejection fraction, stroke volume of both groups were higher than those before treatment, the blood pressure, heart rate and serum NT-proBNP, galectin-3 , ET-1, cystatin C levels were lower than before treatment, and LVFS, LVEF, SV levels of the patients in the observation group were significantly higer than those of the control group(P<0.05), the blood pressure, heart rate and serum NT-proBNP, galectin-3 , ET-1, cystatin C levels were lower than those of the control group (P<0.05). Conclusion: Levosimendan combined with Naoxintong Capsule could improve the therapeutic effect of acute heart failure with higher safety and reduce the levels of serum NT- proBNP, Galectin- 3, ET- 1 and Cystatin C.